GLP-1 RAs are a class of pharmacological agents that mimic the action of endogenous GLP-1 and have been approved by the FDA and EMA for the treatment of T2DM and obesity (Table 1) [27,28]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.